{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:14:29Z","timestamp":1794856469642,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["633784"],"award-info":[{"award-number":["633784"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-026-01662-6","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:13:57Z","timestamp":1778289237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The contribution of rare germline variants to the immune landscape of breast cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Felipe","family":"Rojas-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Canisius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Keeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber N.","family":"Hurson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas U.","family":"Ahearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L.","family":"Andrulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bia\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona M.","family":"Blows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjeet K.","family":"Bolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa H.","family":"Cessna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Chang-Claude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Chanock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Devilee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Dunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Hollestelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo M.","family":"Horlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jakubowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandt","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Kaaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Lissowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Manoochehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad U.","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H. M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong R.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas F.","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Raza","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Garc\u00eda-Closas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D. P.","family":"Pharoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"1","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","volume":"7","author":"K El Bairi","year":"2021","unstructured":"El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, et al. The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7(1):150.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"key":"1662_CR3","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/annonc\/mdz095.003","volume":"30","author":"S Loi","year":"2019","unstructured":"Loi S, Schmid P, Aktan G, Karantza V, Salgado R. 4O - relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. Ann Oncol. 2019;30:iii2.","journal-title":"Ann Oncol"},{"issue":"15","key":"1662_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SMA Mahmoud","year":"2011","unstructured":"Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949\u201355.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1662_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"1","key":"1662_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12885-016-2732-0","volume":"16","author":"J Shou","year":"2016","unstructured":"Shou J, Zhang Z, Lai Y, Chen Z, Huang J. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs\u202f: a systematic review and meta-analysis. BMC Cancer. 2016;16(1):687.","journal-title":"BMC Cancer"},{"issue":"1","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40487-022-00214-3","volume":"11","author":"E Allison","year":"2023","unstructured":"Allison E, Edirimanne S, Matthews J, Fuller SJ. Breast cancer survival outcomes and tumor-associated macrophage markers: a systematic review and meta-analysis. Oncol Ther. 2023;11(1):27\u201348.","journal-title":"Oncol Ther"},{"key":"1662_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3389\/fimmu.2018.00470","volume":"9","author":"M Shen","year":"2018","unstructured":"Shen M, Wang J, Ren X. New insights into tumor-infiltrating B lymphocytes in breast cancer: clinical impacts and regulatory mechanisms. Front Immunol. 2018;9:470. https:\/\/doi.org\/10.3389\/fimmu.2018.00470.","journal-title":"Front Immunol"},{"issue":"1","key":"1662_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12935-021-02004-9","volume":"21","author":"Y Qin","year":"2021","unstructured":"Qin Y, Peng F, Ai L, Mu S, Li Y, Yang C, et al. Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):310.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"1662_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354\u201360.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J ImmunoTher Cancer. 2016;4(1):59.","journal-title":"J ImmunoTher Cancer."},{"issue":"21","key":"1662_CR12","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1200\/JCO.21.01536","volume":"40","author":"VMT de Jong","year":"2022","unstructured":"de Jong VMT, Wang Y, ter Hoeve ND, Opdam M, Stathonikos N, J\u00f3\u017awiak K, et al. Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy. J Clin Oncol. 2022;40(21):2361\u201374.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556\u201367.","journal-title":"N Engl J Med"},{"issue":"2","key":"1662_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2021.01.011","volume":"54","author":"RW Sayaman","year":"2021","unstructured":"Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, et al. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54(2):367-86.e8.","journal-title":"Immunity"},{"key":"1662_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1126\/scitranslmed.aal4922","volume":"9","author":"E Nolan","year":"2017","unstructured":"Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9:393.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1662_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-022-06786-y","volume":"197","author":"J Ogony","year":"2023","unstructured":"Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, et al. Immune cells are increased in normal breast tissues of BRCA1\/2 mutation carriers. Breast Cancer Res Treat. 2023;197(2):277\u201385.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1662_CR17","doi-asserted-by":"publisher","first-page":"e24720","DOI":"10.4161\/onci.24720","volume":"2","author":"S Loi","year":"2013","unstructured":"Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7):e24720.","journal-title":"Oncoimmunology"},{"issue":"8","key":"1662_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"L Emens","year":"2021","unstructured":"Emens L, Molinero L, Loi S, Rugo H, Schneeweiss A, Di\u00e9ras V, et al. Atezolizumab and nab-Paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1662_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","volume":"1","author":"RM Samstein","year":"2021","unstructured":"Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 2021;1(12):1188\u2013203.","journal-title":"Nat Cancer"},{"issue":"5","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428\u201339.","journal-title":"N Engl J Med."},{"key":"1662_CR21","doi-asserted-by":"crossref","unstructured":"Bernstein AJ, Keeman R, Hurson AN, Blows FM, Bolla MK, Miller JL, et al. Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer. iScience. 2026;29(2):114759.","DOI":"10.1016\/j.isci.2026.114759"},{"issue":"7","key":"1662_CR22","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/s41436-018-0361-5","volume":"21","author":"K Lee","year":"2019","unstructured":"Lee K, Seifert B, Shimelis H, Ghosh R, Crowley S, Carter N, et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Genet Med. 2019;21(7):1497\u2013506.","journal-title":"Genet Med"},{"issue":"23","key":"1662_CR23","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","volume":"34","author":"M Schmidt","year":"2016","unstructured":"Schmidt M, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank M, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol. 2016;34(23):2750\u201360.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1662_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher M, Witten DM, Jain P, O\u2019Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310\u20135.","journal-title":"Nat Genet"},{"issue":"D1","key":"1662_CR25","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2019","unstructured":"Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1662_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","volume":"14","author":"L Dorling","year":"2022","unstructured":"Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, Gonz\u00e1lez-Neira A, et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine. 2022;14(1):51.","journal-title":"Genome Medicine"},{"issue":"7","key":"1662_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/0266476042000214501","volume":"31","author":"S Ferrari","year":"2004","unstructured":"Ferrari S, Cribari-Neto F. Beta Regression for Modelling Rates and Proportions. J Appl Stat. 2004;31(7):799\u2013815.","journal-title":"J Appl Stat"},{"issue":"9","key":"1662_CR28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/2041-210X.13234","volume":"10","author":"JC Douma","year":"2019","unstructured":"Douma JC, Weedon JT. Analysing continuous proportions in ecology and evolution: a practical introduction to beta and Dirichlet regression. Methods Ecol Evol. 2019;10(9):1412\u201330.","journal-title":"Methods Ecol Evol"},{"issue":"2","key":"1662_CR29","doi-asserted-by":"publisher","first-page":"e3940","DOI":"10.1002\/ecs2.3940","volume":"13","author":"EA Geissinger","year":"2022","unstructured":"Geissinger EA, Khoo CLL, Richmond IC, Faulkner SJM, Schneider DC. A case for beta regression in the natural sciences. Ecosphere. 2022;13(2):e3940.","journal-title":"Ecosphere"},{"key":"1662_CR30","doi-asserted-by":"publisher","first-page":"674192","DOI":"10.3389\/fimmu.2021.674192","volume":"12","author":"J Goldberg","year":"2021","unstructured":"Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, et al. The immunology of hormone receptor positive breast cancer. Front Immunol. 2021;12:674192.","journal-title":"Front Immunol"},{"key":"1662_CR31","unstructured":"R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. 2020."},{"issue":"2","key":"1662_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v034.i02","volume":"34","author":"F Cribari-Neto","year":"2010","unstructured":"Cribari-Neto F, Zeileis A. Beta Regression in R. J Stat Softw. 2010;34(2):1\u201324.","journal-title":"J Stat Softw"},{"issue":"3","key":"1662_CR33","doi-asserted-by":"publisher","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","volume":"8","author":"N Mavaddat","year":"2022","unstructured":"Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022;8(3):e216744.","journal-title":"JAMA Oncol."},{"issue":"1","key":"1662_CR34","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1038\/s41467-023-38271-5","volume":"14","author":"M Pagadala","year":"2023","unstructured":"Pagadala M, Sears TJ, Wu VH, P\u00e9rez-Guijarro E, Kim H, Castro A, et al. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response. Nat Commun. 2023;14(1):2744.","journal-title":"Nat Commun"},{"issue":"6024","key":"1662_CR35","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"issue":"1","key":"1662_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41467-018-07927-y","volume":"10","author":"AM Heijink","year":"2019","unstructured":"Heijink AM, Talens F, Jae LT, van Gijn SE, Fehrmann RSN, Brummelkamp TR, et al. BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity. Nat Commun. 2019;10(1):100.","journal-title":"Nat Commun"},{"key":"1662_CR37","doi-asserted-by":"publisher","first-page":"795048","DOI":"10.3389\/fimmu.2021.795048","volume":"12","author":"L Ou","year":"2021","unstructured":"Ou L, Zhang A, Cheng Y, Chen Y. The cGAS-STING pathway: a promising immunotherapy target. Front Immunol. 2021;12:795048. https:\/\/doi.org\/10.3389\/fimmu.2021.795048.","journal-title":"Front Immunol"},{"issue":"1","key":"1662_CR38","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1038\/s41467-019-11048-5","volume":"10","author":"T Reisl\u00e4nder","year":"2019","unstructured":"Reisl\u00e4nder T, Lombardi EP, Groelly FJ, Miar A, Porru M, Di Vito S, et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun. 2019;10(1):3143.","journal-title":"Nat Commun"},{"key":"1662_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1200\/PO.19.00350","volume":"4","author":"T O\u2019Meara","year":"2020","unstructured":"O\u2019Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K, et al. Immunological differences between immune-rich estrogen receptor-positive and immune-rich triple-negative breast cancers. JCO Precis Oncol. 2020;4:767\u201379.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1662_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hep.32335","volume":"77","author":"H Ma","year":"2023","unstructured":"Ma H, Kang Z, Foo TK, Shen Z, Xia B. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway. Hepatology. 2023;77(1):33\u201347.","journal-title":"Hepatology"},{"issue":"2","key":"1662_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2019.02.011","volume":"153","author":"CB Morse","year":"2019","unstructured":"Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, et al. Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecol Oncol. 2019;153(2):217\u201322.","journal-title":"Gynecol Oncol"},{"issue":"6230","key":"1662_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"13","key":"1662_CR43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331(13):1135\u201344.","journal-title":"JAMA"},{"key":"1662_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2019.02.007","volume":"45","author":"C Belli","year":"2019","unstructured":"Belli C, Duso BA, Ferraro E, Curigliano G. Homologous recombination deficiency in triple negative breast cancer. Breast. 2019;45:15\u201321.","journal-title":"Breast"},{"issue":"12","key":"1662_CR45","doi-asserted-by":"publisher","first-page":"e1509820","DOI":"10.1080\/2162402X.2018.1509820","volume":"7","author":"M Sobral-Leite","year":"2018","unstructured":"Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, et al. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018;7(12):e1509820.","journal-title":"Oncoimmunology"},{"issue":"8","key":"1662_CR46","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/jnci\/djaf070","volume":"117","author":"M Abubakar","year":"2025","unstructured":"Abubakar M, Duggan MA, Fan S, Pfeiffer RM, Lawrence S, Mutreja K, et al. Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes. J Natl Cancer Inst. 2025;117(8):1673\u201388.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1662_CR47","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","volume":"28","author":"S Groha","year":"2022","unstructured":"Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022;28(12):2584\u201391.","journal-title":"Nat Med"},{"issue":"12","key":"1662_CR48","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","volume":"28","author":"CA Taylor","year":"2022","unstructured":"Taylor CA, Watson RA, Tong O, Ye W, Nassiri I, Gilchrist JJ, et al. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28(12):2592\u2013600.","journal-title":"Nat Med"},{"issue":"2","key":"1662_CR49","doi-asserted-by":"publisher","first-page":"e005852","DOI":"10.1136\/jitc-2022-005852","volume":"11","author":"B Wu","year":"2023","unstructured":"Wu B, Qi L, Chiang H-C, Pan H, Zhang X, Greenbaum A, et al. BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity. J Immunother Cancer. 2023;11(2):e005852.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1662_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41467-019-13894-9","volume":"11","author":"E Goulielmaki","year":"2020","unstructured":"Goulielmaki E, Ioannidou A, Tsekrekou M, Stratigi K, Poutakidou IK, Gkirtzimanaki K, et al. Tissue-infiltrating macrophages mediate an exosome-based metabolic reprogramming upon DNA damage. Nat Commun. 2020;11(1):42.","journal-title":"Nat Commun"},{"issue":"1","key":"1662_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):127.","journal-title":"Signal Transduct Target Ther"},{"key":"1662_CR52","unstructured":"Breast Cancer Association Consortium (BCAC). BCAC TIIC data. BCAC datasets access see BCAC website. EGA. (2026). https:\/\/ega-archive.org\/datasets\/EGAD50000002125."},{"key":"1662_CR53","unstructured":"Rojas-Rodr\u00edguez F. RareGermline_ImmuneBC. Github 2026. Available from: https:\/\/github.com\/SchmidtGroupNKI\/RareGermline_ImmuneBC."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01662-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:11:47Z","timestamp":1783051907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01662-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01662-6","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All women involved provided written informed consent. Each study met local approval by the ethical committee and\/or institutional review board listed in Additional file 2: Table S1. All studies conform to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}